Provided by Tiger Trade Technology Pte. Ltd.

CMS

15.060
-0.180-1.18%
Volume:10.77M
Turnover:162.74M
Market Cap:36.75B
PE:22.57
High:15.350
Open:15.240
Low:14.910
Close:15.240
52wk High:15.630
52wk Low:6.649
Shares:2.44B
HK Float Shares:2.44B
Volume Ratio:1.83
T/O Rate:0.44%
Dividend:0.31
Dividend Rate:2.05%
EPS(LYR):0.667
ROE:9.91%
ROA:5.58%
PB:1.91
PE(LYR):22.57
PS:4.14

Loading ...

Assessing China Medical System Holdings (SEHK:867) Valuation After CMS D017 Clinical Trial Approval

Simply Wall St.
·
Feb 05

China Medical System Receives Regulatory Nod to Begin Trials of CMS-D017

MT Newswires Live
·
Feb 04

CMS (00867) Self-Developed Innovative Drug CMS-D017 Capsule Receives Clinical Trial Approval Notice for Complement-Mediated Kidney Diseases

Stock News
·
Feb 03

China Medical System Holdings Limited Approval of Drug Clinical Trials for Cmkd Indication of Innovative Drug CMS-D017

THOMSON REUTERS
·
Feb 03

China Medical System Holdings erhält Zulassung für klinische Studie mit CMS-D017 in China

Reuters
·
Feb 03

China Medical System Holdings - CMS-D017 Capsules Receive Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
Feb 03

CMS (00867) Announces January 2026 Monthly Return with No Share Capital Changes

Bulletin Express
·
Feb 02

Hong Kong Stocks Movement | CMS (00867) Rises Over 3% as Institutions Note Ruxolitinib Cream's Domestic Approval Could Fill the Gap in Vitiligo Targeted Therapy

Stock News
·
Feb 02

CICC Maintains "Outperform" Rating on CMS (00867), Raises Target Price to HK$16.5

Stock News
·
Feb 02

China Medical System Holdings Limited Approval of Clinical Trials for Pnh of Innovative Drug Complement Factor B Inhibitor CMS-D017

THOMSON REUTERS
·
Jan 30

China Medical System - CMS-D017 Capsules Obtain Drug Clinical Trial Approval From Nmpa

THOMSON REUTERS
·
Jan 30

China Medical System Holdings Receives NMPA Approval to Begin Clinical Trials for CMS-D017

Reuters
·
Jan 30

China Medical System Unit Secures New Drug Application Approval in China for Vitiligo Drug

MT Newswires Live
·
Jan 30

CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo

Stock News
·
Jan 30

China Medical System Holdings - New Drug Application of Ruxolitinib Phosphate Cream Approved in China

THOMSON REUTERS
·
Jan 30

China Medical System Holdings Wins NMPA Approval for Ruxolitinib Cream for Vitiligo

Reuters
·
Jan 30

With 51% ownership, China Medical System Holdings Limited (HKG:867) insiders have a lot riding on the company's future

Simply Wall St.
·
Jan 29

CMS Securities Initiates Coverage on CMS (00867) with "Strongly Recommend" Rating, Citing Innovation and Internationalization Driving Commercial Leader into New Phase

Stock News
·
Jan 21

An Insider At China Medical System Holdings Lowered Their Holding Recently

Simply Wall St.
·
Jan 08

China Medical System Holdings (SEHK:867): Valuation Check After Y-3 Stroke Drug NDA Acceptance and Phase III Success

Simply Wall St.
·
Dec 17, 2025